Riskpilot← Back to searchSign inGet full accessEviderm Institute AB
ABActiveOrg 5567876908Bergshamra Allé 9Other education n.e.c. · NACE 8559Est. 20091 employees
Revenue 2025
SEK 836K
+33% vs 2024
EBITDA margin
-33.9%
+22% vs 2024
Equity ratio
96.6%
Financial strength
Net profit 2025
SEK 67K
+163% vs 2024
| Revenue | SEK 836K | +33% |
| EBITDA | SEK -283K | +22% |
| Net profit | SEK 67K | +163% |
| Total assets | SEK 6,4M | +4% |
| Equity | SEK 6,2M | +1% |
| Employees | 1 | — |
Legal name
Eviderm Institute AB
Org number
5567876908
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
26 augusti 2009
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Lodén, Lena Marie
Company purpose
Föremålet för bolagets verksamhet är bedriva rådgivning, utveckling och handel med hudvårdsprodukter och därmed förenlig verksamhet.
Address
Bergshamra Allé 9
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 926 | 1 276 | 727 | 630 | 836 |
| Staff expenses | — | −564 | −296 | — | — |
| EBITDA | 219 | −108 | −315 | −364 | −283 |
| Depreciation & amort. | −0 | — | — | −0 | −0 |
| EBIT | 219 | −108 | −315 | −364 | −283 |
| Net financials | 214 | 7 | 131 | 257 | 349 |
| Profit before tax | 558 | 199 | −184 | −107 | 67 |
| Tax | −130 | −63 | — | −0 | −0 |
| Net profit | 428 | 136 | −184 | −107 | 67 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 7 895 | 7 024 | 6 782 | 6 184 | 6 408 |
| Equity | 6 976 | 6 912 | 6 529 | 6 122 | 6 188 |
| Long-term debt | 378 | 72 | 253 | 0 | 0 |
| Short-term debt | 240 | 40 | 0 | 62 | 220 |
| Total debt | 618 | 112 | 253 | 62 | 220 |
EBITDA margin
-33.9%
This company
15.8%
Market median
-315% vs market
20212025
Equity ratio
96.6%
This company
38.2%
Market median
+153% vs market
20212025
Return on equity
1.1%
This company
18.4%
Market median
-94% vs market
20212025
Net profit margin
8.0%
This company
8.1%
Market median
-1% vs market
20212025
Asset turnover
0.13×
This company
1.12×
Market median
-88% vs market
20212025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
ES Audit | Audit | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Eviderm Institute AB (this company)
Eviderm Oy ABEVIDERM OY ABBoard members of Eviderm Institute AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eva Susanne Lundholm | Audit | 0 companies |
| Agneta Ulrika Ringaby | Deputy Board Member | 0 companies |
| Lena Marie Lodén | Board of Directors | 0 companies |